IMMUNOGENIC PEPTIDE AGAINST GROUP A STREPTOCOCCUS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 30, 2023
app pub date -
May 24, 2023
filing date -
Aug 23, 2017
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully